decamethonium

Decamethonium is a synthetic depolarizing neuromuscular blocking agent used primarily in anesthesia to induce short-term muscle paralysis. Structurally related to acetylcholine as a quaternary ammonium compound with a decane backbone and terminal trimethylated amines on each end (decane‑1,10‑diamine core), it acts as a partial agonist at the nicotinic acetylcholine receptor at the motor endplate. Upon binding these receptors—mimicking acetylcholine—it causes persistent depolarization of the muscle membrane. Because it is not rapidly degraded by cholinesterase enzymes in the synaptic cleft like endogenous acetylcholine is (unlike non-depolarizing agents), this sustained depolarization renders skeletal muscles unresponsive to further stimulation and results in paralysis. Decamethonium was historically used for short procedures requiring rapid onset and brief duration of muscle relaxation but has largely been discontinued from clinical use due to side effects and availability of safer alternatives[1][2][3][4][5]. It does not provide analgesia or unconsciousness.

Brand names

Syncurine

Other names

decamethonium bromidetrimethyl-[10-(trimethylazaniumyl)decyl]azanium dibromiden,n,n,n',n',n'-hexamethyldecane-1,10-diaminium dibromide